1-8 of 8
Paul W. Manley, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP)

Peter Schuld, PhD, Stephan Grzesiek, PhD, Johannes Schlotte, Judith M Habazettl, PhD, Wolfgang Jahnke, PhD, Louise Barys, MS, Sandra W Cowan-Jacob, PhD, Alice Loo, MS, Andrea Wiget, Paul W. Manley, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34–35.
https://doi.org/10.1182/blood-2020-140968
Published: 2020
Journal Articles

Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate

Marc Botteman, MSc, MA, Matthew Magestro, Alaa Fadhil Alwan, MD, Paul W Manley, PhD, Oleg Zernovak, MD, Richard C. Woodman
Journal: Blood
Blood (2012) 120 (21): 4439.
https://doi.org/10.1182/blood.V120.21.4439.4439
Published: 2012
Journal Articles

Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells.

David A Irvine, roMB, ChB, Bin Zhang, MD, PhD, Elaine K Allan, BSc, Tessa L Holyoake, PhD, MB, ChB, FRCP, FRCPath, FRSE, Marion Dorsch, PhD, Paul W Manley, PhD, Ravi Bhatia, MD, PhD, Mhairi Copland, PhD, BSc, MB, ChB, MRCP, FRCPath
Journal: Blood
Blood (2009) 114 (22): 1428.
https://doi.org/10.1182/blood.V114.22.1428.1428
Published: 2009
Journal Articles

Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.

Andrea Davies, PhD, Athina Giannoudis, PhD, Claire M. Lucas, BSc, Robert J. Harris, PhD, Paul W. Manley, PhD, Munir Pirmohamed, PhD, FRCP, FRCP(E), Richard E. Clark, MA, MD, FRCP, FRCPat
Journal: Blood
Blood (2007) 110 (11): 2364.
https://doi.org/10.1182/blood.V110.11.2364.2364
Published: 2007
Journal Articles

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karoline Sonneck, MD, Alexander Gruze, Puchit Samorapoompichit, MD, Karl J. Aichberger, MD, Francis Y. Lee, PhD, Paul W. Manley, PhD, Doriano Fabbro, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD
Journal: Blood
Blood (2006) 108 (11): 526.
https://doi.org/10.1182/blood.V108.11.526.526
Published: 2006
Journal Articles

Identification of Bcr/Abl Point Mutations Conferring Resistance to the Abl Kinase Inhibitor AMN107 by a Random Mutagenesis Study.

Arghya Ray, PhD, Sandra Cowan-Jacob, PhD, Paul W. Manley, PhD, Jurgen Mestan, PhD, James D. Griffin, MD
Journal: Blood
Blood (2005) 106 (11): 494.
https://doi.org/10.1182/blood.V106.11.494.494
Published: 2005
Journal Articles

Generation of Resistance Cell Lines to AMN107, a New Inhibitor of BCR-ABL and Its Effects on Cell Lines Sensitive and Resistant to Imatinib.

Francois-xavier Mahon, MD, PhD, Valerie Lagarde, Paul W. Manley, PhD, Jean-Max Pasquet, PhD, Beatrice Turcq, PhD, Josy Reiffers, MD
Journal: Blood
Blood (2004) 104 (11): 4670.
https://doi.org/10.1182/blood.V104.11.4670.4670
Published: 2004
Journal Articles

AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.

James D. Griffin, MD, Doriano Fabbro, PhD, Gabriele Fendrich, PhD, Brian Huntly, MD, PhD, Sandra Jacob, PhD, Andrew Kung, MD, PhD, Jurgen Mestan, PhD, Ellen Weisberg, PhD, D. Gary Gilliland, MD, PhD, Paul W. Manley, PhD
Journal: Blood
Blood (2004) 104 (11): 551.
https://doi.org/10.1182/blood.V104.11.551.551
Published: 2004